Sofosbuvir – EPO

Sofosbuvir – EPO

On Sep 13, 2018 European Patent Office (EPO) maintained patent covering sofosbuvir compound in amended form after hearing in opposition proceedings.
According to news published, Médecins Sans Frontières (MSF – Doctors Without Borders), announced the decision, said it “is gravely disappointed with the European Patent Office’s decision to uphold US pharmaceutical corporation Gilead’s Sciences’ patent related to the key hepatitis C drug sofosbuvir.” Médecins Sans Frontières (MSF) along with 3 other parties filed post grant opposition to EP 2604620 patent in March 2017. EPO held oral proceeding on Sep 13, 2018 & maintained patent in amended form. EP’’620 is set to expire in Apr 2024. SPC has been filed in many countries & if granted would expire in Mar/Apr 2029.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved